Skip to content

Clinical value of procalcitonin and C-reactive protein in early prediction of anastomotic leakage after laparoscopic rectal cancer surgery: a multicenter prospective study

Clinical value of procalcitonin and C-reactive protein in early prediction of anastomotic leakage after laparoscopic rectal cancer surgery: a multicenter prospective study

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100055000
Enrollment
Unknown
Registered
2021-12-30
Start date
2020-06-30
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal cancer

Interventions

Gold Standard:The diagnostic criteria for anastomotic leakage in the ''Expert Consensus on the Standardization of Diagnosis and Registration of Postoperative Complications in Gastrointestinal Tumor Su
Index test:Procalcitonin,&#32
protein

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Those who voluntarily participated in this study and signed a written informed consent; 2. Those aged 18-75 years; 3. Those diagnosed with rectal cancer by colonoscopy biopsy before surgery; 4. Patients with no distant metastasis confirmed by imaging before surgery; 5. Laparoscopic free resection and one-stage anastomosis; 6. Postoperative pathology confirmed complete tumor resection.

Exclusion criteria

Exclusion criteria: 1. Patients who are pregnant, lactating or menstruating; 2. Severe heart failure, chronic obstructive pulmonary disease and other underlying diseases; 3. Patients with severe infection before surgery; 4. Palliative surgery or Hartmann, Miles surgery; 5. Patients with severe infections other than AL after surgery (such as incision infection, lung infection and urinary tract infection); 6. Those who have participated in other clinical trials within 3 months; 7. In view of a certain disease or situation, the investigator believes that it may put the subject at a significant risk and may interfere with the research results.

Design outcomes

Primary

MeasureTime frame
anastomotic leakage;procalcitonin;C-reactive protein;Sensitivity;Specificity;Negative predictive value, positive predictive value;

Secondary

MeasureTime frame
blood routine;

Countries

China

Contacts

Public ContactTao Kaixiong

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

kaixiongtao@hust.edu.cn+86 13507155452

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026